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KoOBJECTIVES The present study established criteria to differentiate simple from complex bifurcation lesions and
compared 1-year outcomes stratiﬁed by lesion complexity after provisional stenting (PS) and 2-stent techniques using
drug-eluting stents.
BACKGROUND Currently, no criterion can distinguish between simple and complex coronary bifurcation
lesions. Comparisons of PS and 2-stent strategies stratiﬁed by lesion complexity have also not been reported
previously.
METHODS Criteria of bifurcation complexity in 1,500 patients were externally tested in another 3,660 true bifurcation
lesions after placement of drug-eluting stents. The primary endpoint was the occurrence of a major adverse cardiac event
(MACE) at 12 months. The secondary endpoint was the rate of stent thrombosis (ST).
RESULTS Complex (n ¼ 1,108) bifurcation lesions were associated with a higher 1-year rate of MACE (16.8%)
compared with simple (n ¼ 2,552) bifurcation lesions (8.9%) (p < 0.001). The in-hospital ST and 1-year target
lesion revascularization rates after 2-stent techniques in the simple group (1.0% and 5.6%, respectively) were
signiﬁcantly different from those after PS (0.2% [p ¼ 0.007] and 3.2% [p ¼ 0.009], respectively); however,
1-year MACE rates were not signiﬁcantly different between the 2 groups. For complex bifurcation lesions, 2-stent
techniques had lower rates of 1-year cardiac death (2.8%) and in-hospital MACE (5.0%) compared with PS
(5.3%, p ¼ 0.047; 8.4%, p ¼ 0.031).
CONCLUSIONS Complex bifurcation lesions had higher rates of 1-year MACE and ST. The 2-stent and PS techniques
were overall equivalent in 1-year MACE. However, 2-stent techniques for complex lesions elicited a lower rate of cardiac
death and in-hospital MACE but higher rates of in-hospital ST and revascularization at 1 year for simple lesions.
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AB BR E V I A T I O N S
AND ACRONYM S
DK = double kissing
DS = diameter stenosis
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
PS = provisional stenting
SB = side branch
ST = stent thrombosis
TLR = target lesion
revascularization
TVR = target vessel
revascularization
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1267P ercutaneous coronary intervention of bifurca-tion lesions is technically challenging and isoften associated with higher rates of in-
stent restenosis. The ostial side branch (SB) is the
most common site of in-stent restenosis (1,2) after
placement of a drug-eluting stent. Patients with
bifurcation lesions do not beneﬁt from systematic
2-stent strategies, but provisional stenting (PS) using
a jailed wire in the SB has been widely accepted as
the gold standard in the majority of bifurcation le-
sions (1–6). This is based on several clinical trials
(1–6); however, these trials have an important limita-
tion of not being stratiﬁed according to the Medina
classiﬁcation (7). Inclusion of lesion complexity as a
parameter in previous studies might have otherwise
led to different stenting strategies, and conse-
quently, the ﬁnal clinical results might have been
different (8–11).
Most importantly, current classiﬁcations do not
provide more information about the complexity of
bifurcation lesions (10). Therefore, it is too early to
conclude that PS can be considered a ﬁnal solution for
coronary bifurcation lesions (10–12). Accordingly, the
present DEFINITION (Deﬁnitions and impact of com-
plEx biFurcation lesIons on clinical outcomes after
percutaNeous coronary IntervenTIOn using drug-
eluting steNts) study was designed to establish a
practical, easy-to-use classiﬁcation to differentiate
simple from complex bifurcation lesions and analyze
the effect of bifurcation complexity on clinical results
after PS and 2-stent techniques.METHODS
STUDY DESIGN AND PATIENT POPULATION. Between
January 2004 and July 2012, 5,160 patients with at least
1 Medina 1,1,1 and 0,1,1 coronary bifurcation lesion (7)
were prospectively registered. For 1,500 patients
from January 2004 to June 2006 (training group),
confounding factors for composite major adverse car-
diac events (MACE) were selected by logistic regres-
sion analysis. The rate of MACE stratiﬁed by each
confounding factor and combinations of several con-
founding factors were calculated. Deﬁnitions ofChina; kkDaqing Oil General Hospital, Daqing, China; {{Shanghai Ruijin Hosp
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Manuscript received December 13, 2013; revised manuscript received April 1complex and simple bifurcation lesions were
then established according to the predictive
value of the confounding factors.
Finally, these deﬁnitions were externally
tested in 3,660 patients (study group) be-
tween July 2006 and July 2012. Patients in the
study group were divided into 2 pre-speciﬁc
subgroups according to the criteria estab-
lished from the training group: the simple
and complex groups. The ethics committee of
each participating center approved the study
protocol, and each patient provided written
consent.
INCLUSION/EXCLUSION CRITERIA. Only Medina
1,1,1 and 0,1,1 coronary bifurcation lesions
with an SB diameter $2.5 mm by visual estimation
were included in the training and study groups.
The following exclusion criteria were included:
1) SB diameter <2.5 mm; 2) ST-segment elevation
myocardial infarction (MI) <1 week; 3) cardiogenic
shock; 4) a history of coronary artery bypass graft-
ing; 5) use of bare-metal stent; 6) in-stent restenotic
lesions; 7) lesions being treated by classic crush
stenting or the kissing stenting technique; and
8) patients who were already included in any other
clinical study.
STENTING PROCEDURES. The selection of stenting
techniques and of the transradial versus transfemoral
approach was left to the physician’s discretion. Stents
for all implanted lesions were limus-eluting stents,
including the Cypher (Cordis, Johnson & Johnson,
Miami Lakes, Florida); Firebird or Firebird-2 (Micro-
port Co., Shanghai, China); EXCEL, BIOMATRIX FLEX
(Biosensor/Jiwei Co., Shandong, China); Partner
(Lepu Med, Beijing, China); Xience or Xience Prime
(Abbott Vascular, Santa Clara, California); and
Endeavor or Endeavor Resolute (Medtronic, Minne-
apolis, Minnesota). Use of intravascular ultrasound
was left to the physician’s discretion. Stenting tech-
niques have been described previously (3,4,12).
Brieﬂy, ﬁnal kissing balloon inﬂation was recom-
mended after all 2-stent strategies. Kissing balloon
inﬂation was only used after PS if there were any of
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TABLE 1 Baseline Clinical Characteristics in Training and Study Groups
Training Group
(n ¼ 1,550)
Study Group (n ¼ 3,660)
Simple
(n ¼ 2,552)
Complex
(n ¼ 1,108) p Value*
Age, yrs 67  9 65  10 68  9 <0.001
Male 1,162 (77.5) 1,911 (74.9) 873 (78.0) 0.011
Height, cm 165  8 167  7 167  7 0.646
Weight, kg 67  10 68  11 68  11 0.696
Hypertension 1,050 (70.0) 1,851 (72.5) 819 (74.0) 0.373
Diabetes 525 (35.0) 876 (34.3) 498 (45.0) <0.001
Unstable angina 915 (61.0) 1,629 (63.8) 720 (65.0) 0.203
Acute myocardial infarction 135 (9.0) 237 (9.3) 135 (12.2) 0.009
Congestive heart failure 225 (15.0) 411 (16.1) 246 (22.2) <0.001
Left ventricular ejection
fraction <40%
135 (9.0) 144 (5.6) 199 (17.9) <0.001
Current smoker 147 (9.8) 318 (12.5) 75 (6.8) <0.001
Stroke 60 (4.0) 105 (4.1) 33 (3.0) 0.108
Gastrointestinal bleeding 3 (0.2) 6 (0.2) 3 (0.3) 1.000
Hyperlipidemia 720 (48.0) 1,242 (48.6) 513 (46.3) 0.207
White blood cells,  109/l 7.25  0.22 7.52  0.39 7.21  0.17 0.677
Red blood cells,  109/l 4.25  0.51 4.23  0.61 4.23  0.52 0.917
Platelet,  109/l 188.45  65.31 185.7  66.54 202.82  70.14 0.002
Hemoglobin,  109/l 131.19  16.58 131.49  18.39 129.17  17.66 0.114
Fasting glucose, mmol/l 6.27  2.42 6.28  2.46 6.29  2.57 0.861
Cholesterol, mmol/l 4.03  0.94 4.06  0.97 4.05  1.01 0.697
Low-density lipoprotein, mmol/l 2.51  0.86 2.53  0.81 2.56  0.91 0.298
Creatinine, mmol/l 88.33  42.9 85.41  48.11 89.92  49.8 0.015
eGFR <60 ml/min/1.73 m2 5 (3.3) 84 (51.9) 45 (44.1) 0.256
High-sensitivity C-reactive
protein, mg/dl
2.69  0.68 2.67  0.59 2.75  0.68 0.024
Values are mean  SD or n (%). *Indicates the comparison of simple and complex subgroups in the
study group.
eGFR ¼ estimated glomerular ﬁltration rate.
FIGURE 1 Description of Complex Bifurcation Lesion Deﬁnitions
For bifurcation lesions (Medina 1,1,1/0,1,1 with side branch diam-
eter minimally 2.5 mm, major criteria (SB DS and SB lesion length)
plus any 2minor criteria are deﬁned as complex bifurcation lesions.
DS ¼ diameter stenosis; LM ¼ left main; SB ¼ side branch.
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1268Myocardial Infarction ﬂow <3, type B dissection or
greater, and residual diameter stenosis (DS) $70% by
visual estimation. Stenting of the SB in the PS group
was required if Thrombolysis In Myocardial Infarction
ﬂow was <3, the presence of type B dissection
or greater, or residual DS was $70% after kissing
balloon inﬂation. Finally, 2-stent techniques included
double kissing (DK) crush, culotte, T and protrusion,
and traditional T.
MEDICATIONS. All patients were pre-treated with
aspirin and clopidogrel. A 300-mg loading dose of
clopidogrel was administered before the index pro-
cedure if patients were not pre-treated. Intravenous
unfractionated heparin was used to maintain an acti-
vated clotting time between 250 and 300 s throughout
the entire procedure. Creatine kinase-myocardial
band and troponin were dynamically measured until
72 h post-procedure. After discharge, aspirin therapy
was continued indeﬁnitely (100 mg/day for life), and
clopidogrel (75 mg/day) was continued for at least
12 months.
FOLLOW-UP. Clinical follow-up was performed dur-
ing visits or through telephone contact at 1, 6, 8,
and 12 months. Adverse events were monitored
throughout the entire study period. Follow-up coro-
nary angiography was not recommended unless clin-
ically indicated for earlier intervention.
STUDY ENDPOINTS AND DEFINITIONS. The primary
endpoint was the occurrence of MACE at 12 months,
including cardiac death, MI, and target vessel
revascularization (TVR). The secondary endpoint
was the occurrence of stent thrombosis (ST). Aca-
demic Research Consortium deﬁnitions of MI, car-
diac death, target lesion revascularization (TLR),
TVR, angiographic and procedural success, and ST
(13) were used. Lesion speciﬁcities were deﬁned ac-
cording to American Heart Association/American
College of Cardiology criteria (14). Angiographic
patterns of in-stent restenosis were deﬁned by
Mehran’s classiﬁcation (15) and classiﬁed as classes I
through IV. Bifurcation angle and vessel angulation
were deﬁned according to previous studies (16).
Calciﬁcation was identiﬁed as readily apparent
radiopacity within the vascular wall at the site of the
stenosis, and it was classiﬁed as none/mild, moder-
ate (i.e., radiopacity noted only during the cardiac
cycle before contrast injection), and severe (i.e.,
radiopacity noted without cardiac motion before
contrast injection, generally compromising both
sides of the arterial lumen [Figure 1A]). Multiple le-
sions (Figure 1B) included multiple-vessel disease
(deﬁned as $70% stenosis in at least 1 major
TABLE 2 Lesions and Procedural Characteristics in Training and Study Groups
Training Group
(n ¼ 1,500)
Study Group (n ¼ 3,660)
Simple
(n ¼ 2,552)
Complex
(n ¼ 1,108) p Value*
Lesion locations <0.001
Distal left main 38 (2.5) 36 (1.4) 66 (6.0)
LAD diagonal 1,035 (69.0) 1,944 (76.1) 675 (61.0)
Left circumﬂex OM 285 (19.0) 432 (16.9) 327 (29.5)
Distal right coronary artery 67 (4.5) 141 (5.5) 39 (3.5)
Classiﬁcations 0.001
Medina 1,1,1 1,199 (80.0) 2,022 (79.2) 918 (83.0)
Medina 0,1,1 301 (20.0) 531 (20.9) 189 (17.0)
Main vessel
Chronic total occlusion 113 (7.5) 186 (7.3) 117 (10.6) 0.001
Thrombus-containing 71 (4.6) 126 (4.9) 30 (2.7) 0.002
Reference vessel diameter <3.0 mm 173 (11.5) 297 (11.6) 294 (26.6) <0.001
Reference vessel diameter <2.5 mm 345 (23.0) 555 (21.7) 396 (35.8) <0.001
Side branch
Chronic total occlusion 6 (4.0) 84 (3.3) 81 (7.3) <0.001
Thrombus-containing 2 (1.3) 24 (0.9) 3 (0.3) 0.034
Lesion length $10 mm 525 (35.0) 1,002 (39.2) 786 (71.0) <0.001
Severe tortuous 97 (6.5) 126 (4.9) 144 (13.0) <0.001
Reference vessel diameter <3.0 mm 750 (50.0) 1,356 (53.1) 459 (41.5) <0.001
Multivessel disease 1,095 (73.0) 1,668 (65.3) 1,068 (96.5) <0.001
Transradial 1,215 (81.0) 2,248 (88.1) 774 (69.9) <0.001
Pre-dilation
Main vessel 915 (61.0) 1,452 (56.8) 711 (64.2) <0.001
Side branch 450 (30.0) 720 (28.2) 453 (40.9) <0.001
Kissing inﬂation 104 (6.9) 144 (5.6) 126 (11.4) <0.001
Stents per patient 2.71  1.35 2.45  1.22 2.93  1.37 <0.001
Stent diameter, mm 2.88  0.41 2.93  0.41 2.93  0.49 0.676
Stent length, mm 75.0  35.2 64.0  34.8 78.0  39.9 <0.001
Post-dilation in main vessel 1,494 (99.6) 2,544 (99.6) 1,104 (99.7) 1.000
Acute closure of side branch 113 (7.5) 213 (8.3) 69 (6.2) 0.031
Reopen 72 (4.8) 129 (60.6) 39 (56.5) 0.574
Complete revascularization 1,080 (72.0) 2,010 (78.7) 675 (61.0) <0.001
IVUS assessment 451 (30.0) 681 (26.6) 468 (42.3) <0.001
Angiographic success 14,333 (95.5) 2,434 (95.3) 1,052 (95.0) 0.875
Values are n (%) or mean  SD. *Indicates the comparison of simple and complex subgroups in the
study group.
LAD ¼ left anterior descending artery; IVUS ¼ intravascular ultrasound; OM ¼ obtuse marginal.
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1269epicardial vessel and $50% stenosis in at least 1
other major vessel) or $2 lesions separated by at
least a 5-mm normal segment in the target vessel. A
thrombus-containing lesion was deﬁned as a coro-
nary strip, oval- or irregularly-shaped ﬁlling defect
with retention of contrast medium or dye
(Figure 1C). Estimated glomerular ﬁltration rate was
calculated according to the Modiﬁed Diet in Renal
Disease formula (17).
STATISTICAL ANALYSIS. Multiple anatomic factors
for MACE were analyzed in patients from the training
group, and factors with a p value #0.001 with the
highest sensitivity and speciﬁcity were considered
major criteria. Otherwise, factors with a p value
>0.001 were treated as minor criteria. The rates of
MACE stratiﬁed by combinations of each major cri-
terion with any 1 or more minor criteria were calcu-
lated. Sensitivity and speciﬁcity of this classiﬁcation
for MACE were calculated with the receiver-operating
characteristic curve. The deﬁnitions of complex and
simple bifurcation lesions were later established ac-
cording to the predictive value of major plus minor
criteria.
Comparability of baseline characteristics between
the complex and simple groups or between PS and
2-stent subgroups (based on intention-to-treat) was
assessed using a 2-sample t test for continuous vari-
ables or the Fisher exact test for categorical variables.
Analyses of the adjudicated primary and secondary
outcomes were conducted on data from all patients
using Kaplan-Meier estimates and Cox proportional
hazards models. Hazard ratios, 95% conﬁdence in-
tervals, and p values were calculated using models
adjusted for the pre-speciﬁed baseline factors listed
in Tables 1 and 2. Statistical signiﬁcance was taken as
a 2-sided p value <0.05. All analyses were performed
using the statistical program SPSS version 16.0 (IBM,
Chicago, Illinois).TABLE 3 Independent Factors of Major Adverse Cardiac Events at 1 Year After Stenting by Regression Analysis of 1,500 Patients in the Training Group
p Value HR (95% CI) Sensitivity, % Speciﬁcity, %
Major 1: Distal LM bifurcation: SB-DS $70% and SB lesion length $10 mm <0.001 55.2 (21.005–79.437) 80 72
Major 2: Non-LM bifurcation: SB-DS $90% and SB lesion length $10 mm <0.001 66.3 (12.708–98.184) 80 74
Minor 1: Moderate to severe calciﬁcation 0.002 38.7 (24.516–72.695) 64 65
Minor 2: Multiple lesions 0.007 26.8 (4.322–57.004) 68 60
Minor 3: Bifurcation angle <45 0.004 14.1 (9.245–18.018) 64 53
Minor 4: Main vessel RVD <2.5 mm 0.010 9.4 (7.556–14.814) 69 58
Minor 5: Thrombus-containing lesions 0.002 27.2 (4.662–78.301) 66 64
Minor 6: MV lesion length $25 mm 0.010 6.9 (3.879–12.398) 57 66
Major 1 þ any 2 minor 1–6 ¼ complex 87 83
Major 2 þ any 2 minor 1–6 ¼ complex 88 83
CI ¼ conﬁdence interval; DS ¼ diameter stenosis; HR ¼ hazard ratio; LM ¼ left main; MV ¼ multivessel; RVD ¼ reference vessel diameter; SB ¼ side branch.
FIGURE 2 Study Flow Chart
The established criteria were tested externally in 3,660 patients with Medina 1,1,1/0,1,1
bifurcation lesions and a side branch (SB) $2.5 mm. F/U ¼ follow-up.
TABLE 4 Clinical Ou
In-hospital
Myocardial infarction
Cardiac death
Target lesion revascu
Target vessel revasc
Coronary artery bypa
Major adverse cardia
Stent thrombosis
At 1 year
Myocardial infarction
Cardiac death
Target lesion revascu
Target vessel revasc
Coronary artery bypa
Major adverse cardia
Stent thrombosis
Deﬁnite and probabl
Values are n (%) unless ot
Abbreviations as in Tabl
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1270RESULTS
BASELINE CHARACTERISTICS. A total of 1,500 pa-
tients were included in the training group. Baseline
clinical (Table 1), lesions, and procedural (Table 2)
characteristics in the training group were comparable
to those in the study group. Of the 1,500 patients in
the training group, 1-year MACE rate was 16.5%, with
MI, cardiac death, and TVR in 3.8%, 1.3%, and 14.6%
of patients, respectively.tcomes in Complex and Simple Groups of 3,660 Patients
Complex
(n ¼ 1,108)
Simple
(n ¼ 2,552)
Adjusted HR
(95% CI) p Value
75 (6.8) 96 (3.8) 0.62 (0.31–0.92) <0.001
9 (0.8) 9 (0.4) 2.32 (0.92–5.85) 0.076
larization 0 9 (0.4) — 0.066
ularization 0 12 (0.5) — 0.052
ss graft 0 3 (0.1) 0.40 (0.31–0.47) 0.560
c events 75 (6.8) 108 (4.1) 0.97 (0.58–1.06) <0.001
0 9 (0.4) 0.065
78 (7.0) 105 (4.1) 1.77 (1.31–2.39) <0.001
45 (4.1) 27 (1.1) 3.96 (2.45–6.42) <0.001
larization 66 (5.8) 96 (3.8) 0.35 (0.16–0.63) 0.003
ularization 87 (7.9) 126 (4.9) 0.46 (0.21–0.78) 0.001
ss graft 9 (0.8) 3 (0.1) 1.88 (0.63–3.23) 0.004
c events 186 (16.8) 228 (8.9) 0.72 (0.51–0.93) <0.001
18 (1.6) 18 (0.7) 0.72 (0.56–0.84) 0.012
e 12 (1.1) 18 (0.7) 1.54 (0.74–3.21) 0.246
herwise indicated.
e 3.ESTABLISHMENT OF CRITERIA DIFFERENTIATING
SIMPLEX FROM COMPLEX BIFURCATION LESIONS.
Logistic regression of all lesion characteristics from
patients in the training group listed in the Table 2
and entered into the model revealed 8 confounding
factors that correlated with 1-year MACE (p < 0.05)
(Table 3). Of these predictive factors, 2 parameters
(for distal left main bifurcation: SB DS $70% and SB
lesion length $10 mm; for nonleft main bifurcation:
SB DS $90% and SB lesion length $10 mm) had the
highest sensitivity (80%) and speciﬁcity (72% to 74%)
for MACE (all p values <0.001), and these parameters
were deﬁned as major criteria; another 6 parameters
with p values >0.001 were classiﬁed as minor criteria
(Table 3). When each major criterion was combined
with any 2 minor criteria, the sensitivity and speci-
ﬁcity of this new stratiﬁcation were $87% and 83%,
respectively (Table 3).
According to our newly established criteria, 1,108
patients (30%) exhibited complex bifurcations, as
shown in the study ﬂowchart (Figure 2), and the
remaining 2,552 patients (70%) were classiﬁed as
having simple bifurcation lesions. Complex bifurca-
tion lesions were more frequently observed in older
male patients with more comorbidities (e.g., diabetes,
acute MI, renal dysfunction, congestive heart failure),
increased plasma platelet count, and severe
inﬂammation.
CLINICAL OUTCOMES OF COMPLEX AND SIMPLE
BIFURCATION LESIONS IN 3,660 PATIENTS IN THE
STUDY GROUP. Generally, patients with complex
bifurcation lesions had signiﬁcantly higher in-hospital
MACE rates compared with simple bifurcation lesions
(6.8% vs. 4.2%, p < 0.001), which was mainly driven
by increased MIs (6.8% vs. 3.8%, p < 0.001) (Table 4).
The difference in MACE between the complex and
simple subgroups became wider at the 1-year follow-
up (16.8% vs. 8.9%; hazard ratio: 0.72; 95% conﬁ-
dence interval: 0.51 to 0.93; p < 0.001) (Figure 3A), and
signiﬁcant differences in all individual endpoints
were observed between the 2 subgroups (Figures 3B to
3D). Notably, the incidence of overall ST in the com-
plex group was 1.6%, which was signiﬁcantly higher
than 0.7% in the simple group (p ¼ 0.026).
COMPARISON OF CLINICAL OUTCOMES BETWEEN
THE 2-STENT AND THE PS SUBGROUPS. We ﬁrst
studied simple (n ¼ 2,552) bifurcation lesions (as
deﬁned by our criteria) to examine the effect of PS
(n ¼ 1,961, 70%) versus 2-stent techniques (n ¼ 591,
30%) and found that 2-stent techniques were associ-
ated with increased in-hospital ST (1.0% vs. 0.2%,
p ¼ 0.007) (Table 5). At 1-year follow-up, there were
no signiﬁcant differences in MACE, cardiac death, MI,
FIGURE 3 Comparison of the 3,660 Study Patients
Comparison of cumulative (Cum) 1-year survival rate free of major adverse cardiac events (MACE) (A), cardiac death (B), myocardial infarction
(MI) (C), and target vessel revascularization (TVR) (D) between the simple and complex groups.
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1271and TVR between PS and 2-stent techniques in the
simple group (Figure 4), although the TLR rate at
1 year (5.6%) in the 2-stent subgroup was signiﬁ-
cantly higher than that in the in PS subgroup (3.2%)
(p ¼ 0.009) (Table 5). Of 1,961 patients in the PS
group, additional SB stenting was required in 3.0%
(n ¼ 59) of patients according to our angiographic
criteria.
We examined complex bifurcation lesions in the
second analysis (n ¼ 1,108). We found a higher rate of
in-hospital MACE (8.4%) in the PS subgroup (n ¼ 571),
which was signiﬁcantly different from the 2-stent
subgroup (5.0%, p ¼ 0.026), mainly because ofincreased in-hospital MI rate in the PS group (Table 6).
The rates of MACE, MI, and TVR at 1-year in the PS
subgroup was not signiﬁcantly different from that in
2-stent subgroup (Table 6, Figures 5A to 5D). However,
PS was associated with a higher rate of 1-year cardiac
death: 5.3% compared with 2.8% (p ¼ 0.041) in the
2-stent subgroup (Table 6, Figure 5B). Of 571 patients in
the PS subgroup, 18.1% (n¼ 103) crossed over to 2-stent
techniques, and more ﬁnal balloon kissing inﬂation
was required (n ¼ 165, 28.9%). These results were
signiﬁcantly different from the 14.7% in patients in
the PS subgroup with simple bifurcation lesions
(Tables 5 and 6).
TABLE 5 Clinical Ou
3,660 Patients
Final kissing inﬂation
Side branch stenting
In-hospital
Myocardial infarction
Cardiac death
Target lesion revascu
Target vessel revasc
Coronary artery bypa
Major adverse cardia
Stent thrombosis
At 1 year
Myocardial infarction
Cardiac death
Target lesion revascu
Target vessel revasc
Coronary artery bypa
Major adverse cardia
Stent thrombosis
Deﬁnite and proba
Values are n (%) unless ot
PS ¼ provisional stentin
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1272DISCUSSION
We report newly established criteria for the differ-
entiation of simple from complex coronary bifur-
cation lesions in a large patient cohort. The most
important ﬁndings of the present study are the
following: 1) the complex group after drug-eluting
stent has more frequent composite MACE and ST
than the simple group; and 2) 2-stent strategies for
overall bifurcation lesions have 1-year MACE
rates comparable to those with PS. However, pa-
tients with complex bifurcation lesions likely
beneﬁted from 2-stent techniques in terms of car-
diac death.
LESSONS FROM PREVIOUS RANDOMIZED CLINICAL
STUDIES ON BIFURCATION LESIONS. Previous
studies have conﬁrmed that systematically complex
stenting strategies do not provide any advantage
over PS for a given bifurcation lesion (1–7,18,19). As
a result, PS of the SB has become the gold standard
of care for bifurcation lesions. However, the
DKCRUSH-II study (Double Kissing Crush versus
Provisional Stenting Technique for Treatment of
Coronary Bifurcation Lesions) (8) showed reduced
TLR rates after the administration of DK crush over
PS for Medina 1,1,1 and 0,1,1 bifurcation lesions. Thetcomes in 2-Stent and PS Subgroups in the Simple Group of
Simple Group (n ¼ 2,552)
2-Stent
(n ¼ 591)
PS
(n ¼ 1,961)
Adjusted HR
(95% CI) p Value
509 (85.9) 288 (14.7) — <0.001
592 (100.0) 59 (3.0) — <0.001
18 (3.0) 78 (4.0) 0.76 (0.45–1.28) 0.295
0 9 (0.5) — 0.125
larization 3 (0.5) 6 (0.3) 1.66 (0.41–1.66) 0.475
ularization 3 (0.5) 9 (0.5) 1.11 (0.29–4.09) 0.882
ss graft 0 3 (0.2) — 0.926
c events 18 (3.0) 90 (4.6) 0.68 (0.40–1.13) 0.136
6 (1.0) 3 (0.2) 6.68 (1.67–26.80) 0.007
18 (3.0) 87 (4.4) 0.68 (0.40–1.13) 0.136
6 (1.0) 21 (1.1) 0.95 (0.38–2.34) 0.905
larization 33 (5.6) 63 (3.2) 1.78 (1.16–2.74) 0.009
ularization 33 (5.6) 93 (4.7) 1.19 (0.79–1.78) 0.413
ss graft 0 3 (0.2) — 1.000
c events 54 (9.1) 174 (8.9) 1.03 (0.75–1.42) 0.853
6 (1.0) 12 (0.6) 1.66 (0.62–4.45) 0.311
ble 6 (1.0) 12 (0.6) 1.66 (0.62–4.45) 0.311
herwise indicated.
g; other abbreviations as in Table 4.possible explanations for this different result be-
tween the DKCRUSH-II study and others are mainly
discrepancies in the study design and lesion
complexity, which were documented as SB size
(from 2.0 to >2.5 mm), location (distal left main or
nonleft main) and patterns (with or without Medina
1,0,1) of bifurcation lesions, plaque burden (SB DS
varying from 40% to >60%), SB lesion length (5 to
>10 mm), calciﬁed lesions, chronic total occlusion,
acute MI, and the use of 2-stent techniques. The
CACTUS (Coronary Bifurcations: Application of the
Crushing Technique Using Sirolimus-Eluting Stents)
study (5) reported severe plaque burdens (SB DS
>60%) in SB, but classic crush stenting was the only
2-stent technique used, and this technique is infe-
rior to culotte stenting (18) or DK crush stenting
(3,8,20).
Based on the analyses mentioned above, there is
an urgent need for a simple, comprehensive, and
practical criteria that can differentiate simple from
complex bifurcation lesions and guide the selection
of an appropriate stenting approach (2-stent or PS),
such as the SYNTAX (Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Sur-
gery) score (6,21) and NERS (New Risk Stratiﬁcation)
score (22).
FEATURES OF THE PRESENT CRITERIA. An advan-
tage of the current criteria was the successful imple-
mentation in a large external patient population with
true bifurcation lesions (Medina 1,1,1 and 0,1,1) and
SB $2.5 mm in diameter. The Medina 1,0,1 bifurcation
lesion, 1 of the true bifurcation lesions, is commonly
treated using PS from intention-to-treatment, and
these lesions were excluded from our analysis.
Our new criteria include several factors that
contribute to reliable risk stratiﬁcation: 2 levels of
stratiﬁcations (i.e., 2 major and 6 minor elements);
relatively large SB (indicating the high risk of
myocardium at jeopardy); severe SB plaque burden
(not proposed in the Medina classiﬁcation); mod-
erate to severe calciﬁcation and multiple lesions
(2 known factors attributing to poor outcome);
renal and left ventricular dysfunction (2 known
predictors of clinical events); and thrombus-
containing lesions (commonly seen in acute coro-
nary syndrome) and longer or diffuse main vessel
lesions (a known factor of poor stent expansion).
Accordingly, the combination of 1 major and any 2
minor criteria would likely indicate the complexity
of a bifurcation lesion or the high-risk patients
much better than the conventional Medina classi-
ﬁcation, which relies on only main vessel and
SB involvement.
FIGURE 4 Comparison of Patients in the Simple Group
Comparison of cumulative 1-year survival rate free of MACE (A), cardiac death (B), MI (C), and TVR (D) between provisional stenting and 2-stent
approaches. Abbreviations as in Figure 3.
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1273IMPACT OF BIFURCATION COMPLEXITY ON CLINICAL
OUTCOMES. The most frequently used Medina clas-
siﬁcation (7) does not provide sufﬁcient information
about the real complexity of a given bifurcation
lesion because of a lack of lesion speciﬁcities (10,11)
and clinical variables. Moreover, several parameters
(including relatively larger SB, long SB lesion, wide
bifurcation angle, and high risk of hemodynamic
deterioration associated with potential SB occlusion)
have been introduced as indicators for ideal candi-
dates for 2-stent techniques (9), but several ques-
tions are still debated. How large is larger? Howlong is longer? What are the accurate predictors of
acute SB closure? Most importantly, these debated
key points have not been systematically studied in
a prospective clinical trial.
In general, our data clearly showed that complex
bifurcation lesions were associated with more
adverse events compared with simple bifurcation le-
sions in the entire cohort of bifurcation lesions, which
indicates the enhanced predictive power of these
newly established criteria. Our results support the
concept that simpler is better for simple bifurcations,
which account for 70% of bifurcation lesions from our
TABLE 6 Clinical Outcomes in 2-Stent and Provisional Stenting Subgroups in the Complex Group of 3,660 Patients
Complex Group (n ¼ 1,108)
2-Stent
(n ¼ 537)
PS
(n ¼ 571)
Adjusted HR
(95% CI) p Value
Final kissing inﬂation 473 (88.1) 165 (28.9) — <0.001
Side branch stenting 537 (100.0) 103 (18.1) — <0.001
In-hospital
Myocardial infarction 27 (5.0) 48 (8.4) 0.58 (0.35–0.94) 0.026
Cardiac death 3 (0.6) 6 (1.1) 0.53 (0.13–2.12) 0.368
Target lesion revascularization 0 0 — NS
Target vessel revascularization 0 0 — NS
Coronary artery bypass graft 0 0 — NS
Major adverse cardiac events 27 (5.0) 48 (8.4) 0.58 (0.35–0.94) 0.026
Stent thrombosis 0 0 — NS
At 1 year
Myocardial infarction 30 (5.6) 48 (8.4) 0.64 (0.40–1.03) 0.067
Cardiac death 15 (2.8) 30 (5.3) 0.52 (0.28–0.97) 0.041
Target lesion revascularization 33 (6.1) 33 (5.8) 1.07 (0.65–1.75) 0.803
Target vessel revascularization 45 (8.4) 42 (7.4) 1.12 (0.74–1.18) 0.532
Coronary artery bypass graft 6 (1.1) 3 (0.5) 2.14 (0.52–8.58) 0.285
Major adverse cardiac events 81 (15.1) 105 (18.4) 0.79 (0.57–1.08) 0.138
Stent thrombosis 9 (1.7) 9 (1.6) 1.06 (0.42–1.69) 0.899
Deﬁnite and probable 6 (1.1) 6 (1.1) 1.06 (0.34–3.13) 0.917
Possible 3 (0.6) 3 (0.5) 1.06 (0.21–5.28) 0.942
Values are n (%) unless otherwise indicated.
Abbreviations as in Table 5.
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1274data. Why is the 1-year rate of cardiac death after PS
for complex bifurcation lesions double that of 2-stent
techniques? We postulate that residual SB dissection
(invisible on angiography) (23,24) and the progression
of SB lesions (25) induced by kissing balloon inﬂation
might be possible explanations, which is consistent
with the DKCRUSH-II study (8) and intravascular ul-
trasound analysis (25,26). Otherwise, a well-deﬁned
PS technique (proximal optimized technique, imag-
ing supported) would have likely shown improve-
ments in clinical results (27–29), even for complex
bifurcation lesions, as suggested by a consensus from
the European Bifurcation Club (29).
CLINICAL IMPLICATIONS. Our newly established
criteria provide a classiﬁcation of the complexity of
bifurcation lesions, demonstrated by more frequent
MACE and individual endpoints after stenting com-
plex bifurcation. Therefore, we are convinced that
simpler is better for the treatment of simple bifurca-
tion lesions. However, the beneﬁts of 2-stent tech-
niques for complex bifurcation lesions should be
further evaluated in randomized studies.
STUDY LIMITATIONS. The major limitation of the pre-
sent study was its nonrandomized design, which would
likely reduce the power of the ﬁnal conclusions. Thesecond limitation was that we did not calculate how
much of the use of the 2-stent techniques was based on
lesion complexity. The third limitation was the exclusion
of the classic crush technique from the current study due
to more frequent malapposition, as documented by
several intravascular ultrasound studies (27,28), more
cases of MACE and ST based on a previous clinical study
(20), and its common inclusion in our DKCRUSH-I study
(20). Fourth, kissing stenting techniques (including V
stenting and simultaneous kissing stenting) were only
used in 6 patients using bare-metal stents, and these
patients were excluded from our analysis. Finally, quan-
titative coronary analysis was not systematically per-
formed. Regardless, our data from such a large patient
sample provides clinically-driven outcomes (avoiding the
“stenosis-reﬂex”) in a real-world fashion.
CONCLUSIONS
The new criteria proposed in the present study can
differentiate complex from simple bifurcation le-
sions: patients with complex bifurcation lesions had
very poor clinical outcomes. Two-stent and PS tech-
niques exhibited equivalent overall 1-year rates of
MACE. A randomized clinical study is required to
further elucidate the difference in clinical outcomes
FIGURE 5 Comparison of Patients in the Complex Groups
Comparison of cumulative 1-year survival rate free of MACE (A), cardiac death (B), MI (C), and TVR (D) between provisional stenting and 2-stent
approaches. Abbreviations as in Figure 3.
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1275between 2-stent and PS techniques for complex
bifurcation lesions stratiﬁed using our new criteria.
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